• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session

    9/15/22 1:03:40 PM ET
    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADBE alert in real time by email

    Gainers

    • HeartBeam, Inc. (NASDAQ:BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO.
    • NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) gained 43.5% to $24.20 after the company announced Dong-A has licensed its global exclusive development rights of DA-1241 for type 2 diabetes and non-alcoholic fatty hepatitis and DA-1726 for obesity and non-alcoholic fatty hepatitis to NeuroBo.
    • ZW Data Action Technologies Inc. (NASDAQ:CNET) surged 43% to $0.9499. ZW Data Action Technologies reported planned acquisition of Henan Baodun.
    • AMTD Digital Inc. (NYSE:HKD) shares jumped 39.9% to $265.00 after jumping 312% on Wednesday.
    • Nabriva Therapeutics plc (NASDAQ:NBRV) gained 38% to $0.2650 after the company announced it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective on September 16, 2022.
    • Addentax Group Corp. (NASDAQ:ATXG) shares rose 30.2% to $6.22 after jumping 17% on Wednesday.
    • STORE Capital Corporation (NYSE:STOR) jumped 20.3% to $32.22 after the company announced it will be acquired by GIC and Oak Street in a $14 billion transaction.
    • Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) rose 19.4% to $1.1299.
    • Secoo Holding Limited (NASDAQ:SECO) jumped 19.1% to $0.3097 after Aladdin Technology Group agreed to invest RMB1.3 million in the company.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) gained 18% to $1.2036.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) gained 16.2% to $0.24.
    • Republic First Bancorp, Inc. (NASDAQ:FRBK) jumped 15.8% to $3.00 as the company announced a strategic review; in light of inquiries by multiple parties expressing interest in one or more potential strategic transactions with the company.
    • Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) shares rose 13.9% to $0.2449. Sonnet BioTherapeutics, last month, posted a Q3 loss of $0.13 per share.
    • Canoo Inc. (NASDAQ:GOEV) gained 11.7% to $2.9050. Canoo Chairman, CEO Tony Aquila disclosed the purchase of 200k shares of the company’s common stock at an average price of $2.58 per share.
    • Enochian Biosciences, Inc. (NASDAQ:ENOB) rose 11.1% to $2.00 after declining around 6% on Wednesday.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) jumped 10.5% to $0.84.
    • ImmunityBio, Inc. (NASDAQ:IBRX) gained 10% to $7.05.
    • EVgo, Inc. (NASDAQ:EVGO) surged 10.1% to $10.23. EVgo launched Connect the Watts National EV Charging Recognition Program.
    • Wynn Resorts, Limited (NASDAQ:WYNN) climbed 9.9% to $66.70. Credit Suisse upgraded Wynn Resorts from Neutral to Outperform.
    • Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) surged 9.9% to $0.2749.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) gained 9.3% to $0.9710.
    • Ra Medical Systems, Inc. (NASDAQ:RMED) rose 8.9% to $0.1742. Ra Medical Systems recently announced a reverse merger agreement with Catheter Precision.
    • Humana Inc. (NYSE:HUM) rose 8.2% to $496.26 after the company raised FY22 adjusted EPS guidance above estimates. The company also issued FY25 adjusted EPS guidance of $37 per share.
    • Roku, Inc. (NASDAQ:ROKU) jumped 7.7% to $73.58.
    • Amyris, Inc. (NASDAQ:AMRS) gained 6% to $4.15.


    Losers

    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) fell 49.6% to $18.90. Shuttle Pharmaceuticals was awarded new HDAC inhibitor patents for cancer treatment.
    • Color Star Technology Co., Ltd. (NASDAQ:CSCW) dropped 44.8% to $0.0651 after the company announced a $5.6 million registered direct offering priced at $0.08 per unit.
    • IronNet, Inc. (NASDAQ:IRNT) shares dipped 43.9% to $1.2350 after the company reported worse-than-expected Q2 EPS and sales results. The company also withdrew its FY23 guidance in light of management transitions, restructuring and underperformance of current quarter.
    • Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) declined 39.5% to $0.2297 after the company announced the combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 cystic fibrosis.
    • Omeros Corporation (NASDAQ:OMER) fell 28.2% to $3.87 after the company reported Narsoplimab treatment results in critically ill COVID-19 patients in I-SPY COVID trial.
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares fell 24.4% to $0.2685 after gaining around 53% on Wednesday.
    • Aditxt, Inc. (NASDAQ:ADTX) fell 22.8% to $8.83. Aditxt announced a 1-for-50 reverse stock split effective on September 14, 2022.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shares fell 22% to $ 24.05. Rhythm Pharmaceuticals priced its 4.8 million share public offering of common stock at $26 per share.
    • Esports Entertainment Group, Inc. (NASDAQ:GMBL) fell 20.1% to $0.3355 after the company reported a proposed public offering of common stock and warrants.
    • Adobe Inc. (NASDAQ:ADBE) dropped 17% to $307.25 after the company reported Q3 earnings results, issued Q4 sales guidance below estimates and announced it will acquire Figma for approximately $20 billion in cash and stock.
    • Akerna Corp. (NASDAQ:KERN) fell 16.4% to $0.1379.
    • SciSparc Ltd. (NASDAQ:SPRC) declined 15.7% to $0.8129. SciSparc announced it entered into an agreement to acquire Wellution for $20 million.
    • Arconic Corp (NYSE:ARNC) fell 15.1% to $21.64 as the company lowered its FY22 sales outlook from $9.6 billion-$10 billion to $9.2 billion-$9.5 billion. The company also said it sees Q3 Adjusted EBITDA to be in the range of $135 million to $150 million.
    • Wearable Devices Ltd. (NASDAQ:WLDS) fell 14.2% to $ 2.53 on post-IPO volatility after the stock opened for trade on Tuesday.
    • The Oncology Institute, Inc. (NASDAQ:TOI) dropped 13.6% to $4.31.
    • IDEAYA Biosciences, Inc. (NASDAQ:IDYA) fell 13.3% to $10.85. IDEAYA priced its 7.62 million share public offering of common stock at $10.50 per share.
    • NLS Pharmaceutics AG (NASDAQ:NLSP) dropped 13.3% to $0.90.
    • CF Acquisition Corp. VI (NASDAQ:CFVI) fell 13.3% to $12.03.
    • RenovoRx, Inc. (NASDAQ:RNXT) declined 12.5% to $2.30.
    • First Wave BioPharma, Inc. (NASDAQ:FWBI) fell 12.4% to $2.2126 after dropping 12% on Wednesday.
    • Array Technologies, Inc. (NASDAQ:ARRY) declined 11.7% to $17.55. MuddyWatersResearch discussed short report on Zer0es.tv.
    • CVR Energy, Inc. (NYSE:CVI) fell 10.6% to $29.27. Wolfe Research downgraded CVR Energy from Outperform to Peer Perform.
    • Spectrum Brands Holdings, Inc. (NYSE:SPB) dropped 10.5% to $52.56. Spectrum Brands' will oppose attempt to block the U.S. Department of Justice's Opposition to the sale of its Hardware and Home Improvement division to ASSA ABLOY.
    • PBF Energy Inc. (NYSE:PBF) fell 7.7% to $28.09. Shares of oil companies traded lower after rail companies and union negotiators came to a tentative agreement, averting a railroad strike. A strike would have caused supply shortages and lifted oil prices.
    Get the next $ADBE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADBE
    $ADTX
    $AMRS
    $ARNC

    CompanyDatePrice TargetRatingAnalyst
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Roku Inc.
    $ROKU
    2/13/2026$118.00Neutral → Buy
    Rosenblatt
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Roku Inc.
    $ROKU
    2/6/2026$105.00Perform → Outperform
    Oppenheimer
    Adobe Inc.
    $ADBE
    2/3/2026$330.00Overweight → Neutral
    Piper Sandler
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Array Technologies Inc.
    $ARRY
    1/28/2026$11.00Outperform → Neutral
    Robert W. Baird
    Adobe Inc.
    $ADBE
    1/13/2026Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $169 worth of shares (205 units at $0.83), increasing direct ownership by 0.03% to 778,665 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/2/26 5:00:20 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    2/20/26 9:40:28 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Large owner Fertitta Tilman J

    4 - WYNN RESORTS LTD (0001174922) (Issuer)

    2/20/26 4:30:18 PM ET
    $WYNN
    Hotels/Resorts
    Consumer Discretionary

    SEC Form 4 filed by EVP & Chief Commercial Officer Capps J. Travis Jr.

    4 - CVR ENERGY INC (0001376139) (Issuer)

    2/20/26 4:15:32 PM ET
    $CVI
    Integrated oil Companies
    Energy

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roku upgraded by Rosenblatt with a new price target

    Rosenblatt upgraded Roku from Neutral to Buy and set a new price target of $118.00

    2/13/26 8:26:09 AM ET
    $ROKU
    Cable & Other Pay Television Services
    Telecommunications

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    SEC Filings

    View All

    SEC Form 10-K filed by Humana Inc.

    10-K - HUMANA INC (0000049071) (Filer)

    2/19/26 2:26:32 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 10-K filed by CVR Energy Inc.

    10-K - CVR ENERGY INC (0001376139) (Filer)

    2/18/26 4:35:16 PM ET
    $CVI
    Integrated oil Companies
    Energy

    CVR Energy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CVR ENERGY INC (0001376139) (Filer)

    2/18/26 4:30:09 PM ET
    $CVI
    Integrated oil Companies
    Energy

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PBF Energy to Participate in Industry Conferences

    PARSIPPANY, N.J., Feb. 20, 2026 /PRNewswire/ -- PBF Energy Inc. (NYSE:PBF) today announced that members of its management team will participate in the Scotiabank Global Energy Conference on February 25, 2026; the Raymond James Institutional Investor Conference on March 2-3, 2026; and the Wolfe Research Refining Conference on March 5, 2026. Any company presentation materials will be made available on the Investor Relations section of the PBF Energy website at www.pbfenergy.com.About PBF Energy Inc.PBF Energy Inc. (NYSE:PBF) is one of the largest independent refiners in North Amer

    2/20/26 4:15:00 PM ET
    $PBF
    Integrated oil Companies
    Energy

    ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

    Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia to support physicians and healthcare systems throughout the MENA region The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA ANKTIVA will be available for distribution within the next 60 days Initiated discussion with Saudi FDA and UAE regulatory authorities to expand ANKTIVA indications beyond Lung and Bladder cancers ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced a part

    2/20/26 8:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVgo to Report Fourth Quarter and Full Year 2025 Results on March 3

    LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ:EVGO), one of the nation's largest providers of public fast charging infrastructure for electric vehicles (EVs), today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, March 3. This release will be followed by a webcast hosted by members of the EVgo management team at 8 a.m. ET (5 a.m. PT). EVgo Fourth Quarter and Full Year 2025 WebcastWhen: Tuesday, March 3Time: 8 a.m. ET (5 a.m. PT)Live Webcast: https://investors.evgo.com/events-and-presentations A copy of the press release with the financial results and the presentation discussed during the webcast will be available on th

    2/20/26 7:00:00 AM ET
    $EVGO
    EDP Services
    Technology

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Financials

    Live finance-specific insights

    View All

    EVgo to Report Fourth Quarter and Full Year 2025 Results on March 3

    LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ:EVGO), one of the nation's largest providers of public fast charging infrastructure for electric vehicles (EVs), today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, March 3. This release will be followed by a webcast hosted by members of the EVgo management team at 8 a.m. ET (5 a.m. PT). EVgo Fourth Quarter and Full Year 2025 WebcastWhen: Tuesday, March 3Time: 8 a.m. ET (5 a.m. PT)Live Webcast: https://investors.evgo.com/events-and-presentations A copy of the press release with the financial results and the presentation discussed during the webcast will be available on th

    2/20/26 7:00:00 AM ET
    $EVGO
    EDP Services
    Technology

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    CVR Energy Reports Fourth Quarter and Full-Year 2025 Results

    Net loss attributable to CVR Energy stockholders of $110 million for fourth quarter 2025, and net income attributable to CVR Energy stockholders of $27 million for full-year 2025 EBITDA and Adjusted EBITDA of $51 million and $91 million, respectively, for fourth quarter 2025, and $591 million and $393 million, respectively, for full-year 2025 Completed the reversion of the Renewable Diesel Unit ("RDU") at the Wynnewood Refinery back to hydrocarbon processing service in December 2025 Prepaid $75 million in principal of the Term Loan in December 2025 CVR Partners announced a fourth quarter 2025 cash distribution of 37 cents per common unit CVR Energy, Inc. ("CVR Energy" or the

    2/18/26 4:26:00 PM ET
    $CVI
    Integrated oil Companies
    Energy

    $ADBE
    $ADTX
    $AMRS
    $ARNC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by CVR Energy Inc.

    SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

    1/7/25 6:12:47 AM ET
    $CVI
    Integrated oil Companies
    Energy

    Amendment: SEC Form SC 13D/A filed by PBF Energy Inc.

    SC 13D/A - PBF Energy Inc. (0001534504) (Subject)

    12/2/24 5:14:26 PM ET
    $PBF
    Integrated oil Companies
    Energy

    Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

    SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

    11/21/24 4:01:13 PM ET
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care